<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580394</url>
  </required_header>
  <id_info>
    <org_study_id>APC-003</org_study_id>
    <nct_id>NCT04580394</nct_id>
  </id_info>
  <brief_title>Crossover Trial of AD109 in Obstructive Sleep Apnea</brief_title>
  <official_title>Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apnimed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apnimed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to&#xD;
      examine the efficacy and safety of AD109 versus its individual components or placebo in&#xD;
      patients with obstructive sleep apnea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to examine the efficacy and safety of AD109 to treat obstructive sleep&#xD;
      apnea. The study is a four-period single-dose randomized crossover design in which patients&#xD;
      will undergo overnight polysomnographic (PSG) testing with dosing of one of the following 4&#xD;
      treatments: AD109, atomoxetine, R-oxybutynin or placebo. Participants will return 2 weeks&#xD;
      after their final crossover PSG for an end of study (EOS) visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Actual">May 28, 2021</completion_date>
  <primary_completion_date type="Actual">May 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hypoxic Burden (HB)</measure>
    <time_frame>1 night (treatment duration) (8 hours)</time_frame>
    <description>Change in Hypoxic Burden (HB is calculated as the oxygen desaturation 'area under the curve' in association with individual apneas and hypopneas)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apnea-Hypopnea Index (AHI, average number of events for every hour of sleep)</measure>
    <time_frame>1 night (treatment duration) (8 hours)</time_frame>
    <description>Apnea-Hypopnea Index (AHI, average number of events for every hour of sleep)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>AD109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsule administered before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral capsule administered before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-oxybutynin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral capsule administered before sleep</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsule administered before sleep</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD109</intervention_name>
    <description>Oral administration before bed</description>
    <arm_group_label>AD109</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>Oral administration before bed</description>
    <arm_group_label>Atomoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-oxybutynin</intervention_name>
    <description>Oral administration before bed</description>
    <arm_group_label>R-oxybutynin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration before bed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female, between 25 to 65 years of age, inclusive, at the Screening Visit.&#xD;
&#xD;
          -  AHI 10 to &lt;20, or AHI â‰¥20 if meets other PSG criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of narcolepsy.&#xD;
&#xD;
          -  Clinically significant craniofacial malformation.&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery&#xD;
             disease or cardiac failure) or hypertension requiring more than 2 medications for&#xD;
             control. A medication for these purposes is defined by dosage form, such that a&#xD;
             combination antihypertensive medication is considered 1 medication&#xD;
&#xD;
          -  CPAP should not be used for at least 2 weeks prior to first study PSG&#xD;
&#xD;
          -  History of using oral or nasal devices for the treatment of OSA may enroll as long as&#xD;
             the devices are not used during participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Preferred Research Partners, Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teradan Clinical Trials</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurological Center of North Georgia</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

